ClinicalTrials.gg
TerminatedNCT03411837DRSUpdated Oct 12, 2021

Dupilumab Phase 4 Study

An observational study in Atopic Dermatitis, sponsored by Northwestern University. Terminated at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-10-12.

Sponsored by Northwestern University · Observational

Why this study was terminated
Investigator moved from institution.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
46
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Dermatitis, Atopic by Northwestern University — 2 open to participants now, 3 under way, none of them phase 3. Dermatitis, Atopic · Northwestern University.

Started
2017
the only one that year
Observational
6 of 16
none open now
Registered
9th of 16
by date

Among the 16 studies in Dermatitis, Atopic by Northwestern University, this one is the only one that started in 2017, is one of 6 observational ones, and was the 9th registered.

Dermatitis, Atopic

1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 16 studies in Dermatitis, Atopic by Northwestern University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Dermatitis, Atopic by Northwestern University, or all of them as a file.
02

Study summary

The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe AD who are receiving dupilumab as standard-of-care therapy.

Read the detailed description

The investigators will conduct a prospective, longitudinal, non-interventional and observational sub-study of patients receiving dupilumab as normal standard-of-care treatment to assess the efficacy (Specific Aim #1) and safety (Specific Aim #2) of dupilumab for the treatment of moderate-to-severe AD, as well as the prevention and/or mitigation of comorbid health conditions (Specific Aim #3). This study will address the hypotheses that dupilumab will lead to improved long-term control and decreased severity of AD, and that long-term monitoring will shed light on the incidence of adverse drug events.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic Dermatitis, dupilumab
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients diagnosed with moderate-to-severe atopic dermatitis on dupilumab

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged 18 and over who have been diagnosed with Atopic Dermatitis and are using dupilumab therapy as part of standard of care.
  • Parents of adolescents ages 12 to 17 who have been diagnosed with Atopic Dermatitis and are receiving dupilumab off-label for the management of AD.

Exclusion criteria

Exclusion Criteria:

  • Patients not on dupilumab
  • Those who do not comply with the study requirements
  • Those who do not provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
46 participants (actual)
Patient registry
No

Groups and cohorts

  • Dupilumab

    Patients with moderated-to-severe atopic dermatitis who are receiving dupilumab as a standard of care

    Biological: Dupilumab

Interventions

  • BiologicalDupilumab

    Biologic (monoclonal antibody)

    Also known as: Dupixent

06

What researchers measure

Primary outcomes

  1. Quantified Itch Survey

    Time frame: 1 to 3 months

  2. Quantified Sleep Survey

    Time frame: 1 to 3 months

  3. Quantified Quality of Life Survey

    Time frame: 1 to 3 months

Secondary outcomes

  1. Occurrence of any AEs by 24 months

    Will be determined based off of patient reported safety events

    Time frame: 24 months

  2. Occurrence of any infections by 24 months

    Will be determined based off of patient reported safety events

    Time frame: 24 months

  3. Occurrence of any SAEs by 24 months

    Will be determined based off of patient reported safety events

    Time frame: 24 months

07

Study locations

1 site
  • Northwestern University Department of Dermatology
    Chicago, Illinois 60611, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Aug 2019, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2017
First posted
Jan 26, 2018
StartActual
Oct 16, 2017
Primary completionActual
Aug 31, 2019
CompletionActual
Aug 31, 2019
Last update
Oct 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03411837
Responsible party
Jonathan Silverberg (MD, PhD, MPH, Northwestern University) — Principal investigator
First posted
Jan 26, 2018
Start date
Oct 16, 2017
Primary completion
Aug 31, 2019
Completion
Aug 31, 2019
Last update
Oct 12, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion